 Cytochrome P-450 CYP2C8
"Cytochrome P-450 CYP2C8" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A liver microsomal cytochrome P450 hydroxylase that oxidizes a broad spectrum of substrates including STEROIDS, FATTY ACIDS, and XENOBIOTICS. Examples of pharmaceutical substrates for CYP2C8 include; PACLITAXOL; torsemide; and; AMODIAQUINE
| Descriptor ID |
D065727
|
| MeSH Number(s) |
D08.244.453.005.590 D08.244.453.491.368 D08.811.682.690.708.170.010.590 D08.811.682.690.708.170.450.360 D12.776.422.220.453.010.590 D12.776.422.220.453.491.360
|
| Concept/Terms |
Cytochrome P-450 CYP2C8- Cytochrome P-450 CYP2C8
- CYP2C8, Cytochrome P-450
- Cytochrome P 450 CYP2C8
- P-450 CYP2C8, Cytochrome
- Cytochrome P450 MP-20
- Cytochrome P450 MP 20
- P450 MP-20, Cytochrome
- Cytochrome P450, Family 2, Subfamily C, Polypeptide 8
- S-Mephenytoin 4-Hydroxylase
- 4-Hydroxylase, S-Mephenytoin
- S Mephenytoin 4 Hydroxylase
- CYP2C8
- CYPIIC8
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C8".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C8".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C8" by people in this website by year, and whether "Cytochrome P-450 CYP2C8" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2013 | 0 | 4 | 4 | | 2014 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C8" by people in Profiles.
-
Shokati T, Hartmann M, Davari B, Klawitter J, Klawitter J, Christians U. Temsirolimus metabolic pathways revisited. Xenobiotica. 2020 Jun; 50(6):640-653.
-
Schoeppler KE, Aquilante CL, Kiser TH, Fish DN, Zamora MR. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transplant. 2014 May; 28(5):590-7.
-
Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013 Dec; 23(12):721-8.
-
Aquilante CL, Wempe MF, Spencer SH, Kosmiski LA, Predhomme JA, Sidhom MS. Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. Pharmacotherapy. 2013 Sep; 33(9):1000-7.
-
Kadam R, Bourne D, Kompella U, Aquilante C. Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers. Biol Pharm Bull. 2013; 36(2):245-51.
-
Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013 Jan; 75(1):217-26.
-
Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep; 10(9):1489-510.
-
Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics. 2008 Sep; 3(1):7-16.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|